|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/21/22 Biocept Inc. 10-Q 9/30/22 60:7.7M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 2.49M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
11: R1 Document and Entity Information HTML 71K
12: R2 Condensed Balance Sheets HTML 114K
13: R3 Condensed Balance Sheets (Parenthetical) HTML 36K
14: R4 Condensed Statements of Operations (Unaudited) HTML 96K
15: R5 Condensed Statements of Stockholders' Equity HTML 82K
16: R6 Condensed Statements of Cash Flows (Unaudited) HTML 103K
17: R7 The Company, Business Activities and Basis of HTML 135K
Presentation
18: R8 Liquidity HTML 23K
19: R9 Sales of Equity Securities HTML 27K
20: R10 Balance Sheet Details HTML 108K
21: R11 Payor Liability HTML 21K
22: R12 Leases HTML 123K
23: R13 Stock-Based Compensation HTML 111K
24: R14 Common Stock Warrants Outstanding HTML 61K
25: R15 Net Loss per Common Share HTML 45K
26: R16 Commitments and Contingencies HTML 22K
27: R17 Related Party Transactions HTML 23K
28: R18 Subsequent Events HTML 21K
29: R19 The Company, Business Activities and Basis of HTML 143K
Presentation (Policies)
30: R20 The Company, Business Activities and Basis of HTML 106K
Presentation (Tables)
31: R21 Balance Sheet Details (Tables) HTML 108K
32: R22 Leases (Tables) HTML 121K
33: R23 Stock-Based Compensation (Tables) HTML 115K
34: R24 Common Stock Warrants Outstanding (Tables) HTML 61K
35: R25 Net Loss per Common Share (Tables) HTML 43K
36: R26 The Company, Business Activities and Basis of HTML 45K
Presentation - Additional Information (Detail)
37: R27 The Company, Business Activities and Basis of HTML 37K
Presentation - Composition of Net Revenues
Recognized Disaggregated by Source (Detail)
38: R28 The Company, Business Activities and Basis of HTML 37K
Presentation - Summary of Third-Party Payers That
Represent More Than 10% of Total Net Revenues and
Total Accounts Receivable (Detail)
39: R29 Liquidity - Additional Information (Detail) HTML 44K
40: R30 Sales of Equity Securities - Additional HTML 63K
Information (Detail)
41: R31 Balance Sheet Details - Schedule of Fixed Assets HTML 70K
and Accrued Liabilities (Detail)
42: R32 Leases - Additional Information (Detail) HTML 89K
43: R33 Leases - Schedule of Lease Expense (Detail) HTML 28K
44: R34 Leases - Schedule of Represents Maturities of HTML 57K
Operating and Finance Lease Liabilities (Detail)
45: R35 Leases - Supplemental Cash Flow Information HTML 25K
Related to Operating and Finance Leases (Detail)
46: R36 Stock-Based Compensation - Additional Information HTML 43K
(Detail)
47: R37 Stock-Based Compensation - Summary of Stock Option HTML 43K
Activity (Detail)
48: R38 Stock-Based Compensation - Assumptions Used for HTML 35K
Determining Fair Value of Stock Options Under
Black-Scholes Pricing Model (Detail)
49: R39 Stock-Based Compensation - Effects of Stock-Based HTML 33K
Compensation Related to Equity Awards to Employees
and Nonemployees on Condensed Statement of
Operations and Comprehensive Loss (Detail)
50: R40 Common Stock Warrants Outstanding - Summary of HTML 28K
Equity-Classified Common Stock Warrant Activity
(Detail)
51: R41 Common Stock Warrants Outstanding - Additional HTML 26K
Information (Detail)
52: R42 Net Loss per Common Share - Additional Information HTML 25K
(Detail)
53: R43 Net Loss per Common Share - Schedule of HTML 31K
Anti-Dilutive Securities Excluded from
Computations of Diluted Weighted-Average Shares
(Detail)
54: R44 Commitments and Contingencies - Additional HTML 22K
Information (Detail)
55: R45 Related Party Transactions - Additional HTML 26K
Information (Detail)
58: XML IDEA XML File -- Filing Summary XML 106K
56: XML XBRL Instance -- bioc-10q_20220930_htm XML 1.71M
57: EXCEL IDEA Workbook of Financial Reports XLSX 101K
7: EX-101.CAL XBRL Calculations -- bioc-20220930_cal XML 158K
8: EX-101.DEF XBRL Definitions -- bioc-20220930_def XML 324K
9: EX-101.LAB XBRL Labels -- bioc-20220930_lab XML 1.02M
10: EX-101.PRE XBRL Presentations -- bioc-20220930_pre XML 687K
6: EX-101.SCH XBRL Schema -- bioc-20220930 XSD 154K
59: JSON XBRL Instance as JSON Data -- MetaLinks 308± 485K
60: ZIP XBRL Zipped Folder -- 0001564590-22-038094-xbrl Zip 304K
EXHIBIT 32.1
CERTIFICATION
I, Samuel D. Riccitelli, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 as amended (the “Exchange Act”), and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended September 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.
|
Date: November 21, 2022 |
|
|
|
|
|
|
|
|
|
Interim President and Chief Executive Officer (Principal Executive Officer) |
This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/21/22 | |||
| For Period end: | 9/30/22 | NT 10-Q | ||
| List all Filings | ||||